



RECEIVED

APR 02 2003

TECH CENTER 1600/2900

1635

#10

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wheeler et al.)

Group Art Unit: Not yet assigned

Serial No.: 10/020,541)

Conf. No.: 1687)

Filed: April 26, 2002)

For: Methods and Compositions
for Treatment of Ocular Neo-
Vascularization and Neural Injury)

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as First Class
Mail in an envelope addressed to: Box Supplemental IDS-Non-
Fee, Commissioner for Patents, Washington, D.C. 20231 on:

Date of Deposit: 3/25/2003

Person making Deposit: BONNIE FERBESON

Signature: Bonnie Ferguson

Date of Signature: 3/25/03

Examiner: Not yet assigned)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

The reference listed on the attached Supplemental PTO-1449 form is being brought to the attention of the Examiner for consideration in connection with the examination of the above-captioned application.

Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

17400(BAR)

Serial No. 10/020,541

2

PATENT

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 form with initials or other appropriate marks.

No fee is believed due in connection with this communication in accordance with 37 C.F.R. § 1.97(c) and 37 C.F.R. § 1.97(e). However, if Applicant is in error, please charge any fees that may be due in connection with this Information Disclosure Statement to Deposit Account No. 01-0885.

Respectfully Submitted,

Date:

3/21/03

Signature:



Carlos A. Fisher
Registration No. 36,510
ALLERGAN, INC.
T2-7H
Legal Department
2525 Dupont Drive
Irvine, CA. 92612
Tel: (714) 246-4920
Fax: (714) 246-4249

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17400(BAR)	SERIAL NO.: 10/020,541
APPLICANT: Wheeler et al	TITLE:METHODS AND COMPOSITIONS FOR TREATMENT OF OCULAR NEOVASCULARIZATION AND NEURAL INJURY
FILING DATE: April 26, 2002	GROUP: 1646



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	CA WO 01 58240	8/16/2001	PCT			
	CB WO 01 74389	10/11/2001	PCT			
	CC WO 00 40245	7/13/2000	PCT			
	CD WO 0264163	8/22/2002	PCT			

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	CE	Ferrario et al, "Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma", Cancer Research, Vol. 60, No. 15, 8/1/2000, pgs. 4066-4069
	CF	Dimitroff et al, "Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy", Investigational New Drugs, 1999, 17(2), pgs. 121-135
	CG	Chang et al, "Corneal neovascularization", Vol. 12, No. 4, 8/2001, pgs. 242-249

RECEIVED

APR 02 2003

TECH CENTER 1600/2900

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.